EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of dulaglutide on functional and structural MRI changes during cigarette smoking cessation

Clara O Sailer iD, Sophia Lengsfeld, David Coynel iD, Davide Zanchi, Nica Jeanloz, Fabienne Baur, Cemile Bathelt, Katja Bologna, Tanja Vukajlovic, Sandrine A Urwyler, Mirjam Christ-Crain iD, Bettina Winzeler iD

Brain Communications · 31.10.2026 · 8 (6)

DOI: 10.1093/braincomms/fcag410 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain Communications, online erschienen am 27.10.2026. Verfasst von Clara O Sailer und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, 4031 Basel, Switzerland. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Swiss National Science Foundation, Goldschmidt-Jacobson Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 (GLP-1) receptor agonists are investigated for treating addiction. However, it remains unclear whether these agents modulate addiction-related neural circuitry. To address this question, we conducted a predefined neuroimaging subtrial of a larger randomized placebo-controlled trial. While the parent trial enrolled 255 participants with at least moderate nicotine dependence, this mechanistic study included a subset of 71 participants. Participants were randomized to receive either 1.5 mg dulaglutide (N = 35) or placebo (N = 36) for 12 weeks, both administered alongside a standard-of-care regimen of varenicline and behavioural counselling. Structural and functional MRI assessments were performed at baseline and after 12 weeks. Main outcome measures included abstinence rates, changes in craving for cigarette smoking, working memory performance, whole-brain functional activation when exposed to smoking and neutral videos, resting state functional connectivity, and grey matter volume changes from baseline to 12 weeks. We found that 12 weeks of intervention (59 participants completed the 12-week visit (N = 57 usable functional, N = 58 usable structural data)), abstinence rates were comparable between the dulaglutide (54%) and placebo (68%) groups (P = 0.27). Across the entire cohort, craving for cigarette smoking significantly decreased (P < 0.001) and was consistently higher during smoking-cue versus neutral-cue videos (P < 0.001). Working memory improved significantly among participants who achieved smoking abstinence (P = 0.02). While we observed small-to-medium reductions in addiction- and reward-related brain activation from baseline to week 12 across the entire cohort, no significant differences were found between dulaglutide and placebo for any clinical, functional, or structural outcomes. Our findings demonstrate that dulaglutide conferred no incremental benefit over a potent standard-of-care regimen of varenicline and behavioural counselling. These findings are critical for the field, as they suggest a potential ceiling effect of current first-line therapies and define the boundaries of GLP-1 receptor agonists in addiction. While dulaglutide did not modulate cue-induced neural activation in this adjunctive context, this study establishes the feasibility of using longitudinal mechanistic neuroimaging to guide the development of future incretin-based interventions.

Schlagwörter

Stichwörter der Autor:innen

GLP-1 receptor agonistscraving for cigarettesnicotine addictionrewardvarenicline

Autor:innen und Institutionen

  • Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, 4031 Basel, Switzerland.
  • Department of Clinical Research, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
  • Division of Endocrinology, Diabetes, and Metabolism, Mass General Brigham, Harvard Medical School, Boston, MA 02115, USA.
  • Division of Cognitive Neuroscience, Department of Biomedicine, University of Basel, 4055 Basel, Switzerland.
  • Research Cluster Molecular and Cognitive Neurosciences, Department of Biomedicine, University of Basel, 4055 Basel, Switzerland.
  • F. Hoffmann- La Roche, Roche Innovation Centre Basel, 4070 Basel, Switzerland.

ORCID-Profile: Clara O Sailer, David Coynel, Mirjam Christ-Crain, Bettina Winzeler

Förderung

  • NIDDK NIH HHS
  • Swiss National Science Foundation
  • Goldschmidt-Jacobson Foundation
  • University Hospital of Basel
  • Gottfried & Julia Bangerter-Rhyner Foundation
  • Swiss Academy of Medical Sciences
  • National Institute of Diabetes and Digestive and Kidney Disease

Zitieren

APA

Sailer, C. O., Lengsfeld, S., Coynel, D., Zanchi, D., Jeanloz, N., Baur, F., Bathelt, C., Bologna, K., Vukajlovic, T., Urwyler, S. A., Christ-Crain, M., & Winzeler, B. (2026). Effect of dulaglutide on functional and structural MRI changes during cigarette smoking cessation. Brain Communications, 8(6). https://doi.org/10.1093/braincomms/fcag410

Vancouver

Sailer CO, Lengsfeld S, Coynel D, Zanchi D, Jeanloz N, Baur F, et al. Effect of dulaglutide on functional and structural MRI changes during cigarette smoking cessation. Brain Communications. 2026;8(6). doi:10.1093/braincomms/fcag410

BibTeX
@article{Sailer2026,
  author = {Sailer, Clara O and Lengsfeld, Sophia and Coynel, David and Zanchi, Davide and Jeanloz, Nica and Baur, Fabienne and Bathelt, Cemile and Bologna, Katja and Vukajlovic, Tanja and Urwyler, Sandrine A and Christ-Crain, Mirjam and Winzeler, Bettina},
  title = {Effect of dulaglutide on functional and structural MRI changes during cigarette smoking cessation},
  journal = {Brain Communications},
  year = {2026},
  volume = {8},
  number = {6},
  doi = {10.1093/braincomms/fcag410}
}
Kostenlos starten →